Loading...
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)
PURPOSE: Fabry disease is a rare, X-linked, inherited lysosomal storage disorder that can be treated with the enzymes agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme). Currently, there is a global shortage of agalsidase beta, and this has increased global demand for agalsidase alfa. We ass...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Nature Publishing Group
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3908501/ https://ncbi.nlm.nih.gov/pubmed/22498845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/gim.2012.39 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|